# Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines

> **NCT01905215** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 128 (actual)

## Conditions studied

- Infections, Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** RSV vaccine GSK3003892A (formulation 1)
- **BIOLOGICAL:** RSV vaccine GSK3003893A (formulation 2)
- **BIOLOGICAL:** RSV vaccine GSK3003895A (formulation 3)
- **BIOLOGICAL:** RSV vaccine GSK3003896A (formulation 4)
- **BIOLOGICAL:** RSV vaccine GSK3003898A (formulation 5)
- **BIOLOGICAL:** RSV vaccine GSK3003899A (formulation 6)
- **DRUG:** Placebo comparator

## Key facts

- **NCT ID:** NCT01905215
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-22
- **Primary completion:** 2014-04-09
- **Final completion:** 2015-03-16
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01905215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01905215, "Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01905215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*